Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
CMV423
Подписчиков: 0, рейтинг: 0
Clinical data | |
---|---|
Other names | CMV-423; RPR-111423 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C14H14ClN3O |
Molar mass | 275.74 g·mol−1 |
3D model (JSmol) | |
| |
|
CMV423 (2-chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide) is an experimental antiviral drug that has been studied for the treatment of cytomegalovirus (CMV) infection and human herpesvirus 6 (HHV-6) infection. The drug was investigated by Sanofi-Aventis, but its development was discontinued by 2018 before entering clinical trials.